160 related articles for article (PubMed ID: 29562221)
21. Evidence of hydroxyurea activity in children with pretreated desmoid-type fibromatosis: A new option in the armamentarium of systemic therapies.
Ferrari A; Orbach D; Affinita MC; Chiaravalli S; Corradini N; Meazza C; Bisogno G; Casanova M
Pediatr Blood Cancer; 2019 Jan; 66(1):e27472. PubMed ID: 30270493
[TBL] [Abstract][Full Text] [Related]
22. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis.
Constantinidou A; Jones RL; Scurr M; Al-Muderis O; Judson I
Eur J Cancer; 2009 Nov; 45(17):2930-4. PubMed ID: 19767198
[TBL] [Abstract][Full Text] [Related]
23. Desmoid-Type Fibromatosis: Evolving Treatment Standards.
Fiore M; MacNeill A; Gronchi A; Colombo C
Surg Oncol Clin N Am; 2016 Oct; 25(4):803-26. PubMed ID: 27591500
[TBL] [Abstract][Full Text] [Related]
24. Desmoid-type fibromatosis of the head and neck in children: A changing situation.
Paul A; Blouin MJ; Minard-Colin V; Galmiche L; Coulomb A; Corradini N; Boutroux H; Van den Abbeele T; Leboulanger N; Denoyelle F; Garabedian EN; Couloigner V; Orbach D
Int J Pediatr Otorhinolaryngol; 2019 Aug; 123():33-37. PubMed ID: 31059930
[TBL] [Abstract][Full Text] [Related]
25. Desmoid-Type Fibromatosis: Who, When, and How to Treat.
Martínez Trufero J; Pajares Bernad I; Torres Ramón I; Hernando Cubero J; Pazo Cid R
Curr Treat Options Oncol; 2017 May; 18(5):29. PubMed ID: 28439797
[TBL] [Abstract][Full Text] [Related]
26. [Chemotherapy in fibromatoses of childhood and adolescence: results from the Cooperative soft tissue sarcoma study (CWS) and the Italian Cooperative study group (ICG-AIEOP)].
Pilz T; Pilgrim TB; Bisogno G; Knietig R; Koscielniak E; Carli M; Treuner J
Klin Padiatr; 1999; 211(4):291-5. PubMed ID: 10472564
[TBL] [Abstract][Full Text] [Related]
27. Systemic treatment approaches for sporadic desmoid-type fibromatosis: scarce evidence and recommendations.
Kasper B
Oncol Res Treat; 2015; 38(5):244-8. PubMed ID: 25896775
[TBL] [Abstract][Full Text] [Related]
28. Extra-abdominal desmoid fibromatosis: A review of management, current guidance and unanswered questions.
Eastley N; McCulloch T; Esler C; Hennig I; Fairbairn J; Gronchi A; Ashford R
Eur J Surg Oncol; 2016 Jul; 42(7):1071-83. PubMed ID: 26965303
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy for desmoid tumours in association with familial adenomatous polyposis: a report of three cases.
Hamilton L; Blackstein M; Berk T; McLeod RS; Gallinger S; Madlensky L; Cohen Z
Can J Surg; 1996 Jun; 39(3):247-52. PubMed ID: 8640627
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.
Robles J; Keskinyan VS; Thompson M; Davis JT; Mater DV
Pediatr Hematol Oncol; 2020 Aug; 37(5):445-449. PubMed ID: 32129687
[No Abstract] [Full Text] [Related]
31. Correlation of CTNNB1 Mutation Status with Progression Arrest Rate in RECIST Progressive Desmoid-Type Fibromatosis Treated with Imatinib: Translational Research Results from a Phase 2 Study of the German Interdisciplinary Sarcoma Group (GISG-01).
Kasper B; Gruenwald V; Reichardt P; Bauer S; Hohenberger P; Haller F
Ann Surg Oncol; 2016 Jun; 23(6):1924-7. PubMed ID: 26861905
[TBL] [Abstract][Full Text] [Related]
32. Management of serious complications in intra-abdominal desmoid-type fibromatosis.
Bini F; Fiore M; Provenzano S; Bertulli R; Ottini A; Colombo C; Vitellaro M; Greco G; Morosi C; Gronchi A; Casali PG; Palassini E
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1411. PubMed ID: 34165246
[TBL] [Abstract][Full Text] [Related]
33. Desmoid tumors: who, when and how to treat?
Mikhael R; Smith M; Tzanis D; Watson S; Miah AB; Bonvalot S
Curr Opin Oncol; 2022 Jul; 34(4):335-341. PubMed ID: 35837705
[TBL] [Abstract][Full Text] [Related]
34. When is a neoplasm not a neoplasm? When it is a desmoid.
Zippel DB; Temple WJ
J Surg Oncol; 2007 Mar; 95(3):190-1. PubMed ID: 17323331
[No Abstract] [Full Text] [Related]
35. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment.
Fiore M; Rimareix F; Mariani L; Domont J; Collini P; Le Péchoux C; Casali PG; Le Cesne A; Gronchi A; Bonvalot S
Ann Surg Oncol; 2009 Sep; 16(9):2587-93. PubMed ID: 19568815
[TBL] [Abstract][Full Text] [Related]
36. Nationwide trends in the current management of desmoid (aggressive) fibromatosis.
Eastley NC; Hennig IM; Esler CP; Ashford RU
Clin Oncol (R Coll Radiol); 2015 Jun; 27(6):362-8. PubMed ID: 25736277
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.
Quast DR; Schneider R; Burdzik E; Hoppe S; Möslein G
Fam Cancer; 2016 Jan; 15(1):31-40. PubMed ID: 26275868
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of doxorubicin-based and liposomal doxorubicin chemotherapies for patients with extra-abdominal desmoid-type fibromatosis: a systematic review.
Shimizu K; Kawashima H; Kawai A; Yoshida M; Nishida Y
Jpn J Clin Oncol; 2020 Oct; 50(11):1274-1281. PubMed ID: 32700733
[TBL] [Abstract][Full Text] [Related]
39. Intestinal perforation during chemotherapeutic treatment of intra-abdominal desmoid tumor in patients with Gardner's syndrome: report of two cases.
Li W; Zhou Y; Li Q; Tong H; Lu W
World J Surg Oncol; 2016 Jul; 14(1):178. PubMed ID: 27377916
[TBL] [Abstract][Full Text] [Related]
40. Regression of large pelvic desmoid tumor by tamoxifen and sulindac.
Izes JK; Zinman LN; Larsen CR
Urology; 1996 May; 47(5):756-9. PubMed ID: 8650880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
